Ionis Pharmaceuticals, Inc.
IONSHealthcareNASDAQBiotechnology · Last scanned Sep 8, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Ionis Pharmaceuticals, Inc. focuses on Biotechnology services and products. Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. With a market capitalization of $9.65B, it sits in mid-cap territory. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA).
Market Cap
$9.65B
Beta
0.42
P/E (TTM)
—
P/E (Fwd)
-53.20
EPS (TTM)
$-3.48
EPS (Fwd)
$-1.09
ROE
-105.5%
ROA
-12.4%
Cash
$2.10B
Total Debt
$2.19B
Free CF
-$346.8M
52W Change
-9.8%
Annual Financials
Cash vs Debt
Where IONS stands vs its 150-day and 200-day moving averages
As of the August 27, 2026 close, IONS finished 12.37% below its 150-day moving average ($72.30) and 14.18% below its 200-day moving average ($73.83). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is IONS overbought or oversold?
At the August 27, 2026 close, IONS's RSI(14) was 75.0, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $2.10B in cash, though total debt stands at $2.19B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow is running at -$346.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -105.5% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $587.4M (2022) to $943.7M (2025), reflecting a 61% increase over the period.
The relatively low beta of 0.42 suggests IONS is a less volatile holding compared to the broader index. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Ionis Pharmaceuticals, Inc.'s trajectory.